Neuroscience

PharmAla Data to be Published in ACS Chemical Neuroscience

Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research…

10 months ago

Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…

10 months ago

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2…

10 months ago

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human…

10 months ago

Virtua Health partners with care.ai for enterprise-wide implementation of AI-Enabled Virtual Care Solutions for Patients

Virtua Health will leverage care.ai's Smart Care Facility Platform and Always-Aware ambient sensors to enhance patient care, support nursing staff,…

10 months ago

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on…

10 months ago

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain King Faisal Specialist Hospital…

11 months ago

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and…

11 months ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel…

11 months ago

Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11…

11 months ago